Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.

MLA

Lew, Mark F., et al. “Safety and Efficacy of Newly Formulated Selegiline Orally Disintegrating Tablets as an Adjunct to Levodopa in the Management of ‘off’ Episodes in Patients with Parkinson’s Disease.” Current Medical Research and Opinion, vol. 23, no. 4, Apr. 2007, pp. 741–50. EBSCOhost, https://doi.org/10.1185/030079906x167697.

APA

Lew, M. F., Pahwa, R., Leehey, M., Bertoni, J., & Kricorian, G. (2007). Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of “off” episodes in patients with Parkinson’s disease. Current Medical Research and Opinion, 23(4), 741–750. https://doi.org/10.1185/030079906x167697

Chicago

Lew, Mark F, Rajesh Pahwa, Maureen Leehey, John Bertoni, and Greg Kricorian. 2007. “Safety and Efficacy of Newly Formulated Selegiline Orally Disintegrating Tablets as an Adjunct to Levodopa in the Management of ‘off’ Episodes in Patients with Parkinson’s Disease.” Current Medical Research and Opinion 23 (4): 741–50. doi:10.1185/030079906x167697.